Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.32 USD
+0.03 (2.33%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.33 +0.01 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.32 USD
+0.03 (2.33%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.33 +0.01 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat
by Zacks Equity Research
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises
by Zacks Equity Research
Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.
Recent Price Trend in Ocuphire Pharma, Inc. (OCUP) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ocuphire Pharma, Inc. (OCUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
by Zacks Equity Research
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
by Zacks Equity Research
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
Ocuphire Pharma, Inc. (OCUP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Ocuphire Pharma, Inc. (OCUP) closed at $5.86, marking a +0.86% move from the previous day.
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
by Zacks Equity Research
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
by Zacks Equity Research
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
by Zacks Equity Research
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.
Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Ocuphire Pharma, Inc. (OCUP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Ocuphire Pharma, Inc. (OCUP) have performed compared to their sector so far this year.
Ocuphire Pharma, Inc. (OCUP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) closed at $5.36 in the latest trading session, marking a -0.56% move from the prior day.
Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Ocuphire Pharma, Inc. (OCUP) points to a 323.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 Medical Stocks to Buy as Rate Hike Cycle Nears End
by Indrajit Bandyopadhyay
We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.